Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study

[1] Curti B, Jana BR, Javeed M, Makhoul I, Sachdeva K, Hu W et al. Harris, JE, ed. “Renal Cell Carcinoma”. Medscape Reference. WebMD. Retrieved 7 March 2014Search in Google Scholar

[2] Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of renal cell carcinoma. World Journal of Urology. 2005; 23:202-12.10.1007/s00345-004-0466-015812574Search in Google Scholar

[3] McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 23:133-41.10.1200/JCO.2005.03.20615625368Search in Google Scholar

[4] Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell carcinoma. .J Clin Oncol. 2003; 21:3127-32.10.1200/JCO.2003.02.122227532712915604Search in Google Scholar

[5] Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R et al. Medroxyprogestrone, interferon alfa-2a, interleukin-2 or combination of both cytokines in patients with metastatic renal cell carcinoma. Cancer. 2007; 110:2468-77.10.1002/cncr.2305617932908Search in Google Scholar

[6] Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 2:CD001425.10.1002/14651858.CD001425.pub215674877Search in Google Scholar

[7] Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000; 6: 1:S55-S57.Search in Google Scholar

[8] Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000; 18:2972-80.10.1200/JCO.2000.18.16.297210944130Search in Google Scholar

[9] Negrier S1, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med. 1998; 338:1272-8.10.1056/NEJM1998043033818059562581Search in Google Scholar

[10] Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear cell renal carcinoma. N Engl J Med. 2007; 365:125-34.10.1056/NEJMoa06065517215530Search in Google Scholar

[11] Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014; 110:1125-32.10.1038/bjc.2013.832395086124434434Search in Google Scholar

[12] Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013; 49:1287-96.10.1016/j.ejca.2012.12.01023321547Search in Google Scholar

[13] Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):a randomized phase 3 trial. Lancet. 2011; 378:1931-39.10.1016/S0140-6736(11)61613-9Search in Google Scholar

[14] Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2:471-8.Search in Google Scholar

[15] Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9:327-37.Search in Google Scholar

[16] Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003; 9:4641-52.Search in Google Scholar

[17] Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24:16-24.10.1200/JCO.2005.02.2574Search in Google Scholar

[18] Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295:2516-24.10.1001/jama.295.21.2516Search in Google Scholar

[19] Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-16.10.1093/jnci/92.3.205Search in Google Scholar

[20] Trotti A1, Colevas AD, Setser A, Rusch V, Jaques D, Budach V et al. CTCAE v.3.0: development of a comprehensive grading system for adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13:176-81.10.1016/S1053-4296(03)00031-6Search in Google Scholar

[21] Escudier B, Szczlik C, Eisen T, Stadler WM, Schwartz B, Shan M et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2005; 24:380s abstract.10.1200/jco.2005.23.16_suppl.lba4510Search in Google Scholar

[22] Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000; 163:408-17.10.1016/S0022-5347(05)67889-5Search in Google Scholar

[23] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27:3584-90.10.1200/JCO.2008.20.1293364630719487381Search in Google Scholar

[24] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007; 356:115-24.10.1056/NEJMoa06504417215529Search in Google Scholar

[25] Dutcher JP. Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol. 2013; 5:338-53.10.1177/1756287213505672382511224294292Search in Google Scholar

[26] Porta C, Sabbatini R, Procopio G, Paglino C, Galligioni E, Ortega C. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther. 2012; 12:1571-7.10.1586/era.12.8123181412Search in Google Scholar

[27] Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho T et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low risk clear renal cell carcinoma. Cancer. 2014 120:1059-67.10.1002/cncr.28521407502924382589Search in Google Scholar

[28] Hakimi AA, Pham CG, Hsieh JJ. A clear picture of renal cell carcinoma. Nat Genet. 2013; 45:849-50.10.1038/ng.270823892664Search in Google Scholar

[29] Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med. 2013; 369:722-31.10.1056/NEJMoa130398923964934Search in Google Scholar

[30] Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR et al. Clinical factors associated with outcome in patients with metastatic clear cell renal carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007; 110:543-50.10.1002/cncr.2282717577222Search in Google Scholar

[31] Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ et al. Randomised phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012; 30:1371-7.10.1200/JCO.2011.36.413322430274Search in Google Scholar

[32] Wong MK, Mohamed AF, Hauber AB, Yang JC, Liu Z, Rogerio J et al. Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. J Med Econ. 2012; 15:1139-48.10.3111/13696998.2012.70868922808923Search in Google Scholar

[33] Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics. 2011; 29:977-88.10.2165/11593370-000000000-0000021854079Search in Google Scholar